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Diabetes: Epidemiology and 
Complications
Treatment for, and the prognosis of, 
type-1 diabetes mellitus (T1DM) has 
progressed dramatically during the 
last century, but the disease remains a 
major cause of morbidity and mortality. 
Although precise ﬁ  gures are not 
available, over 1 million United States 
citizens currently live with the disease, 
with approximately 30,000 new cases 
diagnosed in the US each year.  The 
total number of people with diabetes 
worldwide is expected to rise to 366 
million in 2030, up from 171 million in 
2000 [1]. 
The exact etiology of the disease 
remains uncertain, but extensive 
research suggests an interaction 
between genetic predisposition and 
environment. In fact, for unknown 
reasons, the incidence of T1DM is 
increasing [2]. Diabetes continues to 
have a tremendous societal impact; 
it is both difﬁ  cult and expensive to 
treat and is associated with a number 
of long-term complications, including 
kidney failure, blindness, nerve 
damage, and premature mortality 
(predominately due to cardiovascular 
problems).
Insulin’s Impact
Banting and Best’s discovery of insulin 
in the early 1920s revolutionized 
diabetes treatment and greatly 
improved the prognosis for what had 
previously been a rapidly fatal disease. 
As shown by the Diabetes Control and 
Complications Trial and the more 
recent Epidemiology of Diabetes 
Interventions and Complications 
trial, insulin therapy has made such 
considerable advances (with better 
insulin formulations and delivery 
systems) that many patients can 
maintain their blood sugar levels within 
a tight range and thereby reduce 
their risk for the disease’s long-term 
complications [3,4,5]. In addition, 
improved treatment of other associated 
conditions such as hypertension and 
hyperlipidemia have helped reduce, or 
at least delay, many of the long-term 
sequelae of diabetes [6]. However, 
problems with insulin-based treatment 
regimens persist. For the patient, 
treatment is expensive and difﬁ  cult, 
requiring strict attention to blood 
glucose monitoring, insulin dosing, 
diet, and exercise. Further, good 
glycemia control is not easily achieved 
by all patients, and even for those able 
to achieve this goal, the treatment is 
not always completely effective.
Promising Directions
Just as ﬁ  nancial investors balance a 
portfolio, with some risky investments 
and others that are more secure, 
researchers will undoubtedly continue 
to further reﬁ  ne “secure” insulin-based 
regimens to help patients achieve even 
better glycemia control. At the same 
time, scientists are pursuing more 
high-risk, high-payoff approaches 
to revolutionize diabetes care. One 
such approach is the closed-loop 
insulin pump (i.e., a pump that 
continuously monitors blood glucose 
and concurrently converts that data 
into appropriate insulin dosing), 
which offers the potential to serve as a 
mechanical pancreas. However, such 
a mechanical system would need be 
fail-safe in order to avoid devastating 
effects (e.g., if the monitor were to 
register a falsely elevated blood glucose 
and thereby trigger an inappropriately 
high insulin dose). In other, similar 
scenarios with no tolerance for error, 
NASA (for instance) sets up systems 
in which two independent monitoring 
systems must come up with similar 
measurements before an action 
is taken. Perhaps the engineering 
obstacles that currently limit the closed-
loop insulin pump can be overcome. 
Other research groups are 
investigating whether the insulin-
producing cells within the pancreas 
(so-called β cells), might be 
promoted to regenerate (in vitro 
or in vivo) to replace the pool of 
insulin-producing cells reduced by 
autoimmune destruction. Another 
promising approach for creating 
cells capable of physiologically 
regulated insulin secretion is to “coax” 
stem cells—undifferentiated cells 
with self-regenerative capacity—to 
differentiate into β-like cells. Gene 
therapy approaches may overcome 
present obstacles and result in cells 
capable of physiologically regulated 
insulin secretion [7]. Lastly, the recent 
completion of the Human Genome 
Project suggests that the genetics 
of diabetes may eventually become 
clearer and may direct appropriate 
preventative approaches. 
While such potential therapies 
remain experimental, pancreas 
transplantation is currently performed 
in patients with complicated diabetes. 
However, a recent report that shows 
beneﬁ  t for patients with both diabetes 
and kidney failure who receive a 
combined pancreas and kidney 
transplant also found that an isolated 
pancreas transplant (for patients with 
preserved kidney function) actually 
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worsened survival [8]. The main point 
is that as we develop new therapies, we 
must maintain humility and recognize 
that newer approaches may have 
great promise, but they also have the 
potential for harm.
History of Islet Transplantation
Islet transplantation has recently 
received considerable interest as 
a potentially deﬁ  nitive treatment 
for diabetes. The concept of islet 
transplantation is not new—
investigators as early as the English 
surgeon Charles Pybus (1882–1975) 
attempted to graft pancreatic tissue to 
cure diabetes. Most, however, credit 
the recent era of islet transplantation 
research to Paul Lacy’s studies dating 
back more than three decades. In 
1967, Lacy’s group described a novel 
collagenase-based method (later 
modiﬁ  ed by Dr. Camillo Ricordi, then 
working with Dr. Lacy) to isolate islets, 
paving the way for future in vitro and in 
vivo islet experiments [9]. Subsequent 
studies showed that transplanted islets 
could reverse diabetes in both rodents 
and non-human primates [10,11] 
(Figure 1). In a summary of the 1977 
Workshop on Pancreatic Islet Cell 
Transplantation in Diabetes, Lacy 
commented on the feasibility of “islet 
cell transplantation as a therapeutic 
approach [for] the possible prevention 
of the complications of diabetes in 
man” [12]. Improvements in isolation 
techniques and immunosuppressive 
regimens ushered in the ﬁ  rst human 
islet transplantation clinical trails in 
the mid-1980s. Yet despite continued 
procedural improvements, only about 
10% of islet recipients in the late 1990s 
achieved euglycemia (normal blood 
glucose). In 2000, Dr. James Shapiro 
and colleagues published a report 
describing seven consecutive patients 
who achieved euglycemia following 
islet transplantation using a steroid-
free protocol and large numbers of 
donor islets, since referred to as the 
Edmonton protocol [13]. This protocol 
has been adapted by islet transplant 
centers around the world and has 
greatly increased islet transplant 
success. 
Current Limitations of Islet 
Transplantation
While signiﬁ  cant progress has been 
made in the islet transplantation ﬁ  eld 
[14], many obstacles remain that 
currently preclude its widespread 
application. Two of the most 
important limitations are the currently 
inadequate means for preventing 
islet rejection, and the limited supply 
of islets for transplantation. Current 
immunosuppressive regimens are 
capable of preventing islet failure for 
months to years, but the agents used 
in these treatments are expensive 
and may increase the risk for speciﬁ  c 
malignancies and opportunistic 
infections. In addition, and somewhat 
ironically, the most commonly used 
agents (like steroids, calcineurin 
inhibitors, and rapamycin) are also 
known to impair normal islet function 
and/or insulin action. Further, like 
all medications, the agents have other 
associated toxicities, with side effects 
such as oral ulcers, peripheral edema, 
anemia, weight loss, hypertension, 
hyperlipidemia, diarrhea, and fatigue 
[15]. Perhaps of greatest concern to 
the patient and physician is the harmful 
effect of certain widely employed 
immunosuppressive agents on renal 
function. For the patient with diabetes, 
renal function is a crucial factor in 
determining long-term outcome, and 
calcineurin inhibitors (tacrolimus 
and cyclosporin) are signiﬁ  cantly 
nephrotoxic. Thus, while some 
patients with a pancreas transplant 
DOI: 10.1371/journal.pmed.0010058.g001
Figure 1. Central Concepts Underlying Islet Transplantation 
The main idea of islet transplantation is to process the organ donor’s pancreas so as to remove the 95% of the gland responsible for its 
exocrine functions (secretion of digestive enzymes) and isolate the 5% of the gland responsible for the endocrine hormone secretion— 
the so-called pancreatic islets. Once isolated, the medical team can infuse the insulin-producing islets through a thin tube, placed in 
the main vein that transports blood from the intestines to the liver. Once infused, the islets are transported by the bloodstream into the 
liver, where they lodge, take up residence, and begin making the right amount of insulin to regulate the blood sugar.
(Illustration: Giovanni Maki)
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tolerate the immunosuppressive agents 
well, and for such patients diabetic 
nephropathy can gradually improve, 
in other patients the net effect 
(decreased risk due to the improved 
blood glucose control, increased 
risk from the immunosuppressive 
agents) may worsen kidney function. 
Indeed, Ojo et al. have published an 
analysis indicating that among patients 
receiving other-than-kidney allografts, 
7%–21% end up with renal failure 
as a result of the transplant and/or 
subsequent immunosuppression [16]. 
Looked at another way, patients 
with heart, liver, lung, or kidney 
failure have a dismal prognosis for 
survival, so the toxicity associated with 
immunosuppression is warranted 
(the beneﬁ  ts of graft survival 
outweigh the risks associated with the 
medications). But for the subset of 
patients with diabetes and preserved 
kidney function, even those with 
long-standing and difﬁ  cult-to-control 
disease, the prognosis for survival is 
comparatively much better. In addition 
to the immunosuppressive toxicities, 
other risks are associated with the 
islet transplant procedure itself, 
including intra-abdominal hemorrhage 
following the transplant, and portal 
vein thromboses. The fact that there 
is already a good alternative to islet 
transplantation (i.e., the modern 
intensive insulin regimen) forces us to 
regard any newer, riskier interventions 
with a critical eye. 
  Like all transplantation 
therapies, islet transplantation is also 
handicapped by the limited donor 
pool. The numbers are striking; at least 
1 million Americans have T1DM, and 
only a few thousand donor pancreata 
are available each year. To circumvent 
this organ shortage problem, 
researchers continue to look for ways 
to grow islets—or at least cells capable 
of physiologically regulated insulin 
secretion—in vitro, but currently only 
islets from cadaveric donors can be 
used to restore euglycemia. Further 
exacerbating the problem (and unlike 
kidney, liver, and heart transplants, 
where only one donor is needed for 
each recipient) most islet transplant 
patients require islets from two or more 
donors to achieve euglycemia. Lastly, 
the current methods for islet isolation 
need improvement, since only about 
half of attempted isolations produce 
transplant-ready islets.
While islet transplantation research 
has made important progress and 
the success stories are encouraging, 
the long-term safety and efﬁ  cacy 
of the procedure remain unclear. 
Other concerns relating to the ﬁ  eld 
include questions about the impact of 
having insulin-producing foreign cells 
within the hepatic parenchyma, the 
long-term consequences of elevated 
portal pressures resulting from the 
islet infusion, and the fact that islet 
recipients can be sensitized against 
donor tissue types, making it more 
difﬁ  cult to ﬁ  nd a suitable donor 
should another life-saving transplant 
be required in the future. Also, very 
few islet transplant recipients have 
remained euglycemic without the 
use of any exogenous insulin beyond 
four years post-transplant. Thus, while 
most islet recipients achieve better 
glycemia control and suffer less serious 
hypoglycemia, islet transplantation 
continues to fall short of the deﬁ  nitive 
diabetes cure. 
Is Islet Transplantation Ready for 
Widespread Use?
While no one suggests that the 
therapy is ready for widespread 
clinical application, another way 
of highlighting current problems 
is to focus on cost. Assuming 
present hurdles were cleared, islet 
transplantation costs approximately 
$150,000 per patient per transplant. 
With over 1 million Americans dealing 
with T1DM, it would cost over $100 
billion to give each patient a single islet 
transplant, with little assurance as yet of 
any long-term beneﬁ  t. In contrast, the 
annual direct cost of a proven therapy 
like intensive insulin treatment is about 
$3,500 per patient [17]. 
The limitations of islet 
transplantation force us to recognize 
that the therapy remains experimental, 
and that many questions must be 
answered before it is incorporated into 
general clinical practice. At the present 
time, we urge a focus on the selection 
of only those patients for whom this 
procedure offers the greatest likelihood 
of beneﬁ  t. Most people with diabetes 
can, with diligence and perseverance, 
implement an insulin regimen that 
maintains tight glucose control while 
avoiding dangerous hypoglycemia. 
However, there are some patients 
who continue to have tremendous 
difﬁ  culty managing their disease 
despite optimal care and effort. Even 
the statement “despite optimal care 
and effort” is difﬁ  cult to deﬁ  ne, and 
we advocate that all patients being 
considered for an islet transplant 
ﬁ  rst be referred for several months 
to specialty teams that are committed 
to diabetes care. Since such patients 
whose diabetes is the most difﬁ  cult 
to control have a poor quality of life, 
islet transplantation offers potential 
beneﬁ  t. Even a low baseline level of 
insulin production by the transplanted 
islets may lower the amount of insulin 
required, while reducing the number 
and severity of hypoglycemic events. 
We also believe the islet transplant 
risk-beneﬁ  t ratio is favorable for those 
with both T1DM and kidney failure 
who are listed for a life-preserving 
kidney transplant; such patients will 
have to take immunosuppressive agents 
after transplant to preserve the kidney 
allograft function, so the islets can be 
added without too much additional 
risk.
Where do we go from here? 
Just as early studies showed islet 
transplantation’s promise, research 
must now overcome the hurdles 
revealed by the recent islet transplant 
experience. New immunomodulatory 
agents offer the greatest hope of 
revolutionizing the ﬁ  eld. New drug 
regimens capable of inducing tolerance 
to the transplanted islets would allow 
recipients to maintain their grafts 
without general immunosuppression 
and its associated toxicities. While 
many targets are currently under 
investigation, none are ready for 
clinical use. We advocate that such 
immunomodulatory approaches 
be tested ﬁ  rst in controlled models 
where the results can be appropriately 
attributed to the agent itself.
Conclusion
Less than a century ago, T1DM was 
invariably a fatal disease. With the 
advent of insulin, the prognosis 
changed overnight, and we have 
continued to witness improvements in 
diabetes care and outcomes. Pancreatic 
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islet transplant has offered renewed 
hope to many patients with diabetes, 
who envision a life free of glucose 
checks and insulin injections. Some 
transplanted patients have enjoyed 
“success” and are pleased with their 
decisions; unfortunately these results 
are not universal. Researchers must 
continue to look for ways to improve 
the procedure while protecting the 
welfare of each individual patient. The 
ﬁ  eld has come a long way, but we must 
remain cautious, as we are treating a 
non-fatal disease for which there is a 
very effective standard therapy.  
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